EGFR and non-small cell lung carcinoma: Whereas most NSCLC patients with EGFR mutations benefit from treatment with EGFR-TKIs, their clinical efficacy of EGFR-TKIs differs among such patients, and almost all individuals eventually develop resistance to these drugs.